Every Form 4 that Semler Scientific, Inc. (SMLR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SMLR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SMLR filings page.
Semler Scientific director Eric Semler reported the automatic disposition of his Semler Scientific common stock and stock options due to the completion of the merger with Strive, Inc. On January 16, 2026, Merger Sub merged into Semler Scientific, which became a wholly owned subsidiary of Strive.
Each share of Semler Scientific common stock outstanding immediately before the effective time was converted into the right to receive 21.05 shares of Strive Class A common stock, plus cash instead of fractional Strive shares, under the Merger Agreement. The filing shows 636,346 shares of common stock held directly and 77,771 shares held indirectly through TCS Capital Advisors, LLC, all disposed of in this conversion.
Each outstanding Semler Scientific stock option, whether vested or unvested, was converted at the effective time into an option to purchase Strive Class A common stock, with the number of underlying Strive shares determined by the same 21.05 exchange ratio and the exercise price adjusted by dividing the prior Semler exercise price by that ratio.
Semler Scientific CEO Douglas Murphy-Chutorian reported the conversion of his Semler equity in connection with the company’s merger into Strive, Inc. On January 16, 2026, an indirect holding of 241,303 shares of Semler common stock, held through a family trust where he and his spouse share voting and investment power, was disposed of and converted under the merger terms.
On the same date, multiple Semler stock options to purchase common stock, with exercise prices ranging from $1.72 to $58.94, were also reported as disposed of, leaving zero Semler options beneficially owned afterward. Under the Agreement and Plan of Merger, each Semler common share outstanding immediately before the effective time was converted into the right to receive Strive Class A common stock at a fixed exchange ratio of 21.05 Strive shares per Semler share, plus cash in lieu of fractional shares, and each Semler stock option was converted into a corresponding option over Strive Class A common stock on adjusted terms.
Semler Scientific director Daniel S. Messina reported the disposition of 11,910 shares of common stock and multiple stock options on January 16, 2026, in connection with the closing of the company’s merger with Strive, Inc. At the merger’s effective time, each outstanding Semler share was converted into the right to receive 21.05 shares of Strive Class A common stock, plus cash in lieu of fractional shares, under the merger agreement. Messina’s outstanding Semler stock options were converted into options to purchase Strive Class A shares, with the number of underlying shares and exercise prices adjusted by the same 21.05 exchange ratio, and any unvested portions of those options fully vested at the effective time.
Semler Scientific director Natalie Brunell reported derivative transactions tied to the closing of a merger with Strive, Inc. On January 16, 2026, Strive Merger Sub, Inc. merged with Semler Scientific under a Merger Agreement dated September 22, 2025, with Semler continuing as a wholly owned subsidiary of Strive.
The filing shows several Semler stock options disposed of on January 16, 2026, including options to buy 4,000 and 7,500 shares of common stock at exercise prices of $17.78 and $31.79, respectively. At the merger’s effective time, each outstanding Semler option, whether vested or unvested, was converted into an option to purchase Strive Class A common stock on the same terms, with the number of underlying shares and exercise price adjusted by the exchange ratio. The unvested portions of these converted options immediately became vested as of the effective time.
Semler Scientific director William H. Chang reported the disposition of his Semler equity interests in connection with the closing of the company’s merger with Strive, Inc. on January 16, 2026. Under the Merger Agreement, each share of Semler common stock outstanding immediately before the effective time was converted into the right to receive 21.05 shares of Strive Class A common stock, plus cash in lieu of any fractional Strive shares, subject to tax withholding.
The Form 4 shows indirect holdings of Semler common stock of 428,682 shares held by W&D Chang Family Trust, 154,074 shares held in six grantor retained annuity trusts, and 241,508 shares held by Chang 2020 GP LP, all reported as disposed of at an indicated price of $0.00 in the merger conversion. It also reports several Semler stock options (covering 4,000, 3,560, 500, 7,125, 1,000, and 27,000 shares) as disposed of, with post‑transaction balances of zero.
At the effective time, each outstanding Semler stock option was converted into an option to purchase Strive Class A common stock using the 21.05 exchange ratio, with the exercise price adjusted accordingly and any unvested portion vesting immediately as of the effective time.
Semler Scientific director reports stock gift to family
A director of Semler Scientific, Inc. reported a Form 4 transaction dated 12/15/2025 involving a gift of 60,000 shares of common stock, coded as transaction type "G" for gift at a price of $0 per share. According to the explanation, these shares were gifted to the reporting person's grandchildren and other family members who do not share his home. Following this transaction, the reporting person beneficially owns 428,682 shares indirectly through W&D Chang Family Trust, 154,074 shares indirectly through six grantor retained annuity trusts, and 241,508 shares indirectly through Chang 2020 GP LP. The filing indicates the individual is a director of Semler Scientific and that the report is filed by one reporting person.
Semler Scientific CEO Douglas Murphy-Chutorian reported stock option activity and share sales. On 11/17/2025 he exercised a stock option to acquire 125,000 shares of Semler Scientific common stock at an exercise price of $2.23 per share. He then sold 57,669 shares at a weighted average price of $20.09 and 12,737 shares at a weighted average price of $20.73, with the filing stating that these sales were made to cover the option exercise price and withholding taxes. The filing also shows a transfer of 54,594 shares from direct ownership to a family trust and a corresponding 54,594-share increase in indirect ownership. After these transactions, Murphy-Chutorian reports beneficial ownership of 241,303 shares held indirectly through a family trust over which he and his spouse share voting and investment power.